Research programme: monoclonal antibody biosimilars - Turgut Ilac

Drug Profile

Research programme: monoclonal antibody biosimilars - Turgut Ilac

Latest Information Update: 29 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Turgut Ilac
  • Developer Merck Millipore; Turgut Ilac
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Non-small cell lung cancer; Rheumatoid arthritis

Most Recent Events

  • 22 Oct 2015 Turgut Ilac and Merck Millipore collaborates to develop biosimilars for Non-small cell lung cancer and Rheumatoid arthritis
  • 22 Oct 2015 Early research in Non-small cell lung cancer in Turkey (Parenteral)
  • 22 Oct 2015 Early research in Rheumatoid arthritis in Turkey (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top